We’re looking forward to the 15th Biennial Ovarian Cancer Research Symposium this week! ? On September 20th, come listen to CEO Dawn Mattoon present our latest data in ovarian cancer screening at 5:40pm in the Washington Ballroom. Then afterwards, stop by our poster, “Performance of an extracellular vesicle based ovarian cancer screening test in longitudinal preclinical samples from women with high grade serous ovarian cancer – an exploratory analysis“ and chat with lead author Sanchari Banerjee, Ph.D. Hope to see you there! #MercyBio #CancerScreening #OvarianCancer
Mercy BioAnalytics, Inc.
生物技术研究
Waltham,Massachusetts 2,881 位关注者
We are making early stage cancer easier to find.
关于我们
Mercy BioAnalytics is on a mission to save lives and relieve suffering across the globe through the early detection of cancer. We have developed a novel liquid biopsy assay platform which interrogates tumor-derived extracellular vesicles, which are abundant in blood and carry information about their cell of origin, enabling detection of cancer even in at the earliest stages.?
- 网站
-
https://www.mercybio.com
Mercy BioAnalytics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Waltham,Massachusetts
- 类型
- 私人持股
- 创立
- 2018
地点
-
主要
880 Winter St
2003
US,Massachusetts,Waltham,02451
Mercy BioAnalytics, Inc.员工
动态
-
The National Ovarian Cancer Audit Report, which was published earlier this week, includes some shocking statistics: 40% of the women diagnosed with ovarian cancer during the study had an ER admission within 28 days of their ovarian cancer diagnosis. Four in ten! Further, women diagnosed via an emergency presentation were 4X more likely to die within 2 months of their diagnosis than women diagnosed through the ‘urgent suspected referral system’ in the U.K. The study included more than 6,000 women in England and Wales who were diagnosed with ovarian cancer in 2021 or 2022, respectively. Unfortunately, but not unexpectedly, 75% of the ovarian cancers diagnosed were stage III or stage IV. The report urges efforts to improve awareness of signs and symptoms of ovarian cancer, and a review of diagnostic pathways. These are important objectives, but we need to go further. These statistics should be unacceptable, and I truly believe they are addressable. Mercy BioAnalytics, Inc. is fiercely committed to advancing our test designed for population screening of postmenopausal women in whom the majority of ovarian cancer occurs. We’re grateful to have received Breakthrough Device Designation from the FDA, and are now working diligently towards our PMA submission. I’m looking forward to discussing our progress at next week’s AACR Ovarian Cancer Research Summit! Find the NOCA's report here: https://lnkd.in/exQDG4Yd
-
The Mercy Team extends a huge thank you to Danielle Sullivan for visiting our office to launch Ovarian Cancer Awareness Month. We deeply appreciate her sharing insights about the incredible work the National Ovarian Cancer Coalition (NOCC) is doing for ovarian cancer patients and caregivers. We are excited about the chance to support the cause and look forward to joining the Together in Teal walk on September 22nd to help build community and raise awareness for ovarian cancer! September is Ovarian Cancer Awareness Month. Almost 20,000 women will be diagnosed with ovarian cancer this year alone. ? To learn more about ovarian cancer advocacy, visit?https://ovarian.org ? To learn more about the important advances in ovarian cancer detection being made by our team, visit?www.mercybio.com ? #NOCC #PatientAdvocacy #EarlyDetection #OvarianCancerAwarenessMonth
-
As Mercy’s summer internship program wraps up, we want to extend our heartfelt thanks to Arielle Feuer and Christopher O'Connell for all your hard work and commitment!? ? Over the past few months, you’ve brought enthusiasm, fresh perspectives, and dedication to team Mercy. We’re proud of the contributions you’ve made, and the skills you’ve developed during your time here. We're honored to have had you as part of the team! ? #MercyBio #SummerInterns #EarlyDetection #CancerScreening
-
Team Mercy took a break from revolutionizing cancer screening to enjoy some well-deserved summer fun and team bonding at Kimball Farms! We’re so grateful for the talented and dedicated individuals who make our team so special. Here’s to many more moments of fun and collaboration on the road to helping patients everywhere! #MercyBio #CancerScreening #SummerPicnic #Kimballfarms
-
August 1st?is Lung Cancer Awareness Day. Did you know that 1 in 16 people will be diagnosed with lung cancer in their lifetime and that 5-year survival is 10 times higher for people diagnosed with localized versus metastatic disease? Early detection is a critical tool to help combat the devastating impact of this disease. At Mercy, we are proud to be developing the Mercy Halo Lung Cancer assay; a high performance, blood-based test designed to detect lung cancer at its earliest stages, when it’s most treatable. ? To learn more about our research on the early detection of lung cancer please visit?www.mercybio.com To learn more about current methods for lung cancer screening, visit?https://lnkd.in/dZM9D6SY #worldlungcancerday #lungcancer #lungcancerawareness #cancerresearch #mercybio #earlycancerdetection
-
We’re pleased to share that we’ve been recognized by the Association for Diagnostics & Laboratory Medicine with the 2024 Disruptive Technology Award! This award aims to evaluate and elevate companies developing new diagnostic tools and technologies that have the potential to improve patient care, such as the groundbreaking Mercy Halo? Ovarian Cancer Screening test, designed to detect ovarian cancer early when it’s most treatable. Congratulations to the other finalists, Dionysus Digital Health and Vitestro, whose technology has the potential to help patients everywhere. And thank you to Adam Bonislawski for the great article! https://lnkd.in/gtQw6k4P #DTAC #ADLM2024 #EarlyCancerDetection #CancerResearch
-
Looking forward to representing Mercy BioAnalytics, Inc. in the ADLM Disruptive Technology Award competition in Chicago next Monday, July 29th. On Tuesday July 30th my colleague Brendan Manning will be speaking in the Distinguished Abstracts session about our landmark study demonstrating unprecedented sensitivity and specificity for the early detection of ovarian cancer in asymptomatic postmenopausal women. If you’re attending ADLM come and say hello!
-
We're pleased to share that our abstract, "Analytical and clinical performance of a novel ovarian cancer screening test in asymptomatic women" has been recognized with a Distinguished Abstract Award at the upcoming ADLM annual meeting. The abstract was also selected for a podium presentation as part of the Distinguished Abstracts session on Tuesday, July 30th. In more good news, Mercy has also been selected as a finalist of the Disruptive Technology Award Competition at ADLM! Come join us at ADLM to learn more about the great things happening at Mercy! https://lnkd.in/grgTtDSe #ADLM #mercybio #earlycancerdetection #cancerresearch
Mercy BioAnalytics Recognized with Distinguished Abstract Award at Association for Diagnostics and Laboratory Medicine (ADLM) Annual Meeting
prnewswire.com
-
On Sunday, the Mercy team proudly participated in the Ovations for the Cure of Ovarian Cancer Walk and Run Against Ovarian Cancer! We walked with survivors, families, and friends affected by this devastating disease and we were inspired by their strength and resilience. Despite uncooperative weather, the Ovations team put on an incredible event, providing awareness, education, and support for all those affected by Ovarian Cancer. Thank you to our amazing team members who joined forces to support this important cause and help make a difference. Together we will create a brighter future by achieving our mission of saving lives through the early detection of cancer. #OvarianCancer #OvarianCancerAwareness #CancerResearch #EarlyDetection #MercyBio
-
+1